Logo image of PHR

PHREESIA INC (PHR) Stock Fundamental Analysis

NYSE:PHR - New York Stock Exchange, Inc. - US71944F1066 - Common Stock

27.21  +0.41 (+1.53%)

After market: 27.21 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PHR. PHR was compared to 39 industry peers in the Health Care Technology industry. PHR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, PHR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year PHR has reported negative net income.
PHR had a positive operating cash flow in the past year.
In the past 5 years PHR always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: PHR reported negative operating cash flow in multiple years.
PHR Yearly Net Income VS EBIT VS OCF VS FCFPHR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -22.03%, PHR is in the better half of the industry, outperforming 62.16% of the companies in the same industry.
Looking at the Return On Equity, with a value of -32.52%, PHR is in the better half of the industry, outperforming 64.86% of the companies in the same industry.
Industry RankSector Rank
ROA -22.03%
ROE -32.52%
ROIC N/A
ROA(3y)-36.15%
ROA(5y)-34.87%
ROE(3y)-47.98%
ROE(5y)-48.8%
ROIC(3y)N/A
ROIC(5y)N/A
PHR Yearly ROA, ROE, ROICPHR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

PHR's Gross Margin of 67.14% is fine compared to the rest of the industry. PHR outperforms 70.27% of its industry peers.
In the last couple of years the Gross Margin of PHR has remained more or less at the same level.
PHR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.22%
GM growth 5Y0.7%
PHR Yearly Profit, Operating, Gross MarginsPHR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

4

2. Health

2.1 Basic Checks

PHR does not have a ROIC to compare to the WACC, probably because it is not profitable.
PHR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PHR has more shares outstanding
Compared to 1 year ago, PHR has a worse debt to assets ratio.
PHR Yearly Shares OutstandingPHR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PHR Yearly Total Debt VS Total AssetsPHR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 5.50 indicates that PHR is not in any danger for bankruptcy at the moment.
PHR's Altman-Z score of 5.50 is amongst the best of the industry. PHR outperforms 81.08% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that PHR is not too dependend on debt financing.
PHR has a Debt to Equity ratio of 0.04. This is comparable to the rest of the industry: PHR outperforms 59.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 5.5
ROIC/WACCN/A
WACC9.85%
PHR Yearly LT Debt VS Equity VS FCFPHR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

PHR has a Current Ratio of 1.74. This is a normal value and indicates that PHR is financially healthy and should not expect problems in meeting its short term obligations.
PHR has a Current ratio of 1.74. This is comparable to the rest of the industry: PHR outperforms 56.76% of its industry peers.
PHR has a Quick Ratio of 1.74. This is a normal value and indicates that PHR is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.74, PHR is in line with its industry, outperforming 56.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.74
Quick Ratio 1.74
PHR Yearly Current Assets VS Current LiabilitesPHR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 20.00% over the past year.
The Revenue has grown by 19.90% in the past year. This is quite good.
The Revenue has been growing by 28.96% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)19.9%
Revenue growth 3Y33.81%
Revenue growth 5Y28.96%
Sales Q2Q%16.57%

3.2 Future

The Earnings Per Share is expected to grow by 25.86% on average over the next years. This is a very strong growth
PHR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.01% yearly.
EPS Next Y0.48%
EPS Next 2Y27.3%
EPS Next 3Y25.86%
EPS Next 5YN/A
Revenue Next Year20.1%
Revenue Next 2Y16.88%
Revenue Next 3Y15.22%
Revenue Next 5Y13.01%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
PHR Yearly Revenue VS EstimatesPHR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
PHR Yearly EPS VS EstimatesPHR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PHR. In the last year negative earnings were reported.
Also next year PHR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHR Price Earnings VS Forward Price EarningsPHR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PHR Per share dataPHR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as PHR's earnings are expected to grow with 25.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.3%
EPS Next 3Y25.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PHR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHREESIA INC

NYSE:PHR (1/17/2025, 8:21:05 PM)

After market: 27.21 0 (0%)

27.21

+0.41 (+1.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)12-09 2024-12-09/amc
Earnings (Next)N/A N/A
Inst Owners97.19%
Inst Owner Change0%
Ins Owners5.05%
Ins Owner Change-1.73%
Market Cap1.58B
Analysts84.21
Price Target30.82 (13.27%)
Short Float %5.11%
Short Ratio6.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.34%
Min EPS beat(2)8.94%
Max EPS beat(2)13.74%
EPS beat(4)4
Avg EPS beat(4)17.89%
Min EPS beat(4)8.94%
Max EPS beat(4)28.19%
EPS beat(8)8
Avg EPS beat(8)19.57%
EPS beat(12)12
Avg EPS beat(12)20.11%
EPS beat(16)14
Avg EPS beat(16)2.1%
Revenue beat(2)0
Avg Revenue beat(2)-0.53%
Min Revenue beat(2)-0.59%
Max Revenue beat(2)-0.48%
Revenue beat(4)1
Avg Revenue beat(4)-0.31%
Min Revenue beat(4)-0.75%
Max Revenue beat(4)0.57%
Revenue beat(8)4
Avg Revenue beat(8)0.46%
Revenue beat(12)8
Avg Revenue beat(12)0.87%
Revenue beat(16)12
Avg Revenue beat(16)2.99%
PT rev (1m)2.67%
PT rev (3m)2.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.21%
EPS NY rev (1m)0%
EPS NY rev (3m)8.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.9
P/FCF N/A
P/OCF 121.21
P/B 6.21
P/tB 16.07
EV/EBITDA N/A
EPS(TTM)-1.12
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)0.22
OCFY0.83%
SpS6.97
BVpS4.38
TBVpS1.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.03%
ROE -32.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.14%
FCFM N/A
ROA(3y)-36.15%
ROA(5y)-34.87%
ROE(3y)-47.98%
ROE(5y)-48.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.22%
GM growth 5Y0.7%
F-Score5
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 84.92%
Cap/Sales 6.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.74
Quick Ratio 1.74
Altman-Z 5.5
F-Score5
WACC9.85%
ROIC/WACCN/A
Cap/Depr(3y)111.11%
Cap/Depr(5y)107.72%
Cap/Sales(3y)10.27%
Cap/Sales(5y)10.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y0.48%
EPS Next 2Y27.3%
EPS Next 3Y25.86%
EPS Next 5YN/A
Revenue 1Y (TTM)19.9%
Revenue growth 3Y33.81%
Revenue growth 5Y28.96%
Sales Q2Q%16.57%
Revenue Next Year20.1%
Revenue Next 2Y16.88%
Revenue Next 3Y15.22%
Revenue Next 5Y13.01%
EBIT growth 1Y45.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year151.48%
EBIT Next 3Y54.42%
EBIT Next 5Y36.41%
FCF growth 1Y91.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y111.63%
OCF growth 3YN/A
OCF growth 5YN/A